Lifeward Successfully Closes on Strategic Partnership with Oramed
Rhea-AI Summary
Lifeward (Nasdaq: LFWD) closed its strategic partnership with Oramed on March 25, 2026, acquiring Oramed's clinical-stage POD™ protein oral delivery technology and positioning the company as a diversified biomedical innovator with an asserted clear path to profitability.
Lifeward gained access to up to $47 million of capital from Oramed and certain investors and accessed $10 million on March 25, 2026; the company also implemented changes to its board of directors.
AI-generated analysis. Not financial advice.
Positive
- Access to $47 million of committed capital
- $10 million of capital accessed on March 25, 2026
- Acquired clinical-stage POD™ protein oral delivery technology
- Strategic move toward a diversified biomedical business
Negative
- POD™ technology remains clinical-stage and not yet commercial
- No revenue or earnings data provided to validate profitability timeline
News Market Reaction – LFWD
On the day this news was published, LFWD declined 3.52%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LFWD was down 1.39% while momentum-screened peers like PAVM and XAIR showed modest upside, and broader sector peers had mixed moves—pointing to a stock-specific reaction rather than a sector-wide move.
Previous Partnership Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | Oramed approval | Positive | +3.2% | Shareholders approved closing the strategic partnership structure with Oramed and funding. |
| Mar 02 | ReWalk collaboration | Positive | -8.4% | Collaboration to expand ReWalk exoskeleton access via dedicated clinic days at a rehab center. |
| Jan 13 | Oramed investment pact | Positive | +9.2% | Announced transformative Oramed investment and POD™ platform acquisition with multi-part funding access. |
| Aug 04 | GCC distribution | Positive | +0.5% | Expanded SportsMed distribution partnership to cover UAE and the broader GCC region. |
| Mar 06 | Workers’ comp deal | Positive | -8.1% | Finalized partnership making CorLife exclusive distributor for ReWalk in workers’ compensation. |
Partnership and collaboration headlines have produced mixed reactions, with both sharp gains and notable selloffs, and an average move of about -0.72%, suggesting no consistently positive premium for such news.
Over the past months, Lifeward has steadily built toward this Oramed partnership. Earlier partnership announcements on Jan 13, 2026 and Mar 13, 2026 detailed the POD™ oral protein delivery acquisition and potential funding of up to $47 million, with mixed but generally positive price reactions. Other collaborations, such as expanding ReWalk access and distribution, have sometimes led to selloffs. Today’s closing of the Oramed deal follows this sequence, formalizing prior agreements that aimed to add biotech upside to the MedTech base.
Historical Comparison
In the past year, Lifeward issued five partnership-related announcements, averaging a -0.72% next-day move, showing that even strategic deals have drawn mixed market reactions.
Partnership news shows a clear progression: initial Oramed investment terms in early 2026, shareholder approval in March, and now formal closing, layered on top of earlier access and distribution partnerships for ReWalk.
Market Pulse Summary
This announcement finalizes Lifeward’s strategic partnership with Oramed, confirming acquisition of the POD™ oral protein delivery technology and access to up to $47 million in capital, including an initial $10 million draw. It follows earlier shareholder approvals and transaction disclosures, continuing the shift toward a diversified biomedical model. Recent history shows mixed market responses to partnership news, so investors may watch how effectively Lifeward deploys this funding, integrates the new platform, and progresses toward its stated path to profitability.
Key Terms
protein oral delivery medical
form 8-k regulatory
AI-generated analysis. Not financial advice.
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP).
The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed’s clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity. Through the new partnership, Lifeward has access to up to
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934 concerning Lifeward, Oramed, the strategic investment and partnership agreement with Oramed (collectively, the “Proposed Transactions”) and other matters. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: Lifeward’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the perceived benefits or opportunities of the Proposed Transactions; expectations regarding the use of proceeds; the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the Proposed Transactions; potential adverse reactions or changes to business relationships resulting from the completion of the Proposed Transactions; and legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Contact:
Almog Adar
Chief Financial Officer
Lifeward
E: media@golifeward.com
E: ir@golifeward.com
